

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 323 171
A2

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 88312251.7

(51) Int. Cl. 4: C07H 19/23 , A61K 31/70

(22) Date of filing: 22.12.88

(30) Priority: 24.12.87 JP 327857/87

(43) Date of publication of application:
05.07.89 Bulletin 89/27(24) Designated Contracting States:
DE FR GB(71) Applicant: KYOWA HAKKO KOGYO CO., LTD.
6-1, Ohte-Machi Itchome
Chiyoda-ku Tokyo(JP)

(72) Inventor: Murakata, Chikara c/o Patent
Department
Kyowa Hakko Kogyo Co. Ltd. 6-1 Ohtemachi
Itchome
Chiyoda-ku Tokyo(JP)
Inventor: Sato, Akira c/o Patent Department
Kyowa Hakko Kogyo Co. Ltd. 6-1 Ohtemachi
Itchome
Chiyoda-ku Tokyo(JP)
Inventor: Kasai, Masaji c/o Patent Department
Kyowa Hakko Kogyo Co. Ltd. 6-1 Ohtemachi


Itchome
Chiyoda-ku Tokyo(JP)
Inventor: Kobayashi, Eiji c/o Patent
Department
Kyowa Hakko Kogyo Co. Ltd. 6-1 Ohtemachi
Itchome
Chiyoda-ku Tokyo(JP)
Inventor: Morimoto, Makoto c/o Patent
Department
Kyowa Hakko Kogyo Co. Ltd. 6-1 Ohtemachi
Itchome
Chiyoda-ku Tokyo(JP)
Inventor: Akinaga, Shiro c/o Patent
Department
Kyowa Hakko Kogyo Co. Ltd. 6-1 Ohtemachi
Itchome
Chiyoda-ku Tokyo(JP)

(74) Representative: Lambert, Hugh Richmond et
al
D. YOUNG & CO. 10 Staple Inn
London, WC1V 7RD(GB)

(54) Novel K-252 derivatives having anti-tumor activity and pharmaceutical compositions containing them.

(57) Pharmaceutically active derivatives of K-252 are disclosed, i.e. compounds of the formula:

EP 0 323 171 A2



wherein R^1 and R^2 are independently H or OH; X represents $COOH$, $COOR$, or CH_2OH ; Y represents H, R or COR ; and Z represents OH, OR or SR, wherein R represents lower alkyl. Such compounds have C-kinase inhibitory activity and are expected to be useful as an active ingredient of anti-tumor pharmaceutical preparations, etc.


NOVEL K-252 DERIVATIVES HAVING ANTI-TUMOR ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

The present invention relates to novel compounds which inhibit protein kinase C (hereafter referred to as C-kinase) and have activities such as anti-tumor activity.

C-kinase is a protein kinase which is activated depending upon phospholipids and calcium and widely distributed over tissues and organs in the living body. In recent years, it has become known that this enzyme plays an extremely important role in cell membrane receptor transduction mechanism in which many hormones, neurotransmitters, etc. are concerned. As examples of physiological response induced by the signal transduction system in which C-kinase participates, there have been reported serotonin release from platelets, lysosomal enzyme release and aggregation, superoxide formation and lysosomal enzyme release from neutrophil leukocytes, epinephrine release from adrenal medulla, secretion of aldosterone from renal glomerulus, secretion of insulin from Langerhans' islet, histamine release from mast cells, acetylcholine release from ileum, contraction of vascular smooth muscle, and the like. C-kinase is also supposed to be concerned in cell growth and carcinogenetic mechanism [Y. Nishizuka, Science, 225 1365 (1984); H. Rasmussen et al., Advance in Cyclic Nucleotide and Protein Phosphorylation Research, vol. 18, p. 159, edited by P. Greengard and G.A. Robinson, Raven Press, New York, 1984]. It has thus been clarified that C-kinase takes part in many important physiological responses *in vivo* and various morbid conditions. Therefore, it is expected that a wide variety of diseases such as diseases of the circular system, inflammatory diseases, allergy and tumor can be prevented or treated by artificially inhibiting C-kinase activity by the use of specific inhibitors, etc.

On the other hand, it has been found that antipsychotic drugs such as trifluoperazine and chlorpromazine, dibenamine and tetracaine which are known as local anesthetics, calmodulin inhibitor W-7 [N-(6-aminoethyl)-5-chloro-1-naphthalenesulfonamide], etc. possess C-kinase inhibitory activity. However, the C-kinase inhibitory activity is not the main activity of these drugs, and they only exhibit low inhibitory activity against C-kinase with low specificity [Y. Nishizuka et al., J. Biol. Chem., 255, 8378 (1980); R.C. Schatzman et al., Biochem. Biophys. Res. Commun., 98, 669 (1981); B.C. Wise et al., J. Biol. Chem., 257, 8489 (1982)].

Further, K-252 and KT-5556 represented by the following formula (II) and K-252 derivatives in which R_A and R_B are modified are known with K-252, see EP-A-0 137 632 and U.S. Patent No. 4,555,402; with KT-5556, see Japanese Published Unexamined Patent Application No. 176531/86; and with the K-252 derivatives, see Japanese Published Unexamined Patent Application Nos. 155284/87 and 155285/87).




K-252 (IIa) : $R_A = \text{CO}_2\text{CH}_3$, $R_B = \text{H}$

KT-5556 (IIb) : $R_A = \text{CO}_2\text{H}$, $R_B = \text{H}$

In EP-A-0 137 632 it is described that K-252 has activity to inhibit histamine release and anti-allergic activity, and in Japanese Published Unexamined Patent Application Nos. 155284.87 and 155285.87, it is described that the K-252 derivatives have C-kinase inhibitory activity and activity to inhibit histamine release. It is described in Japanese Published Unexamined Patent Application No. 176531 86 that KT-5556 has activity to inhibit histamine release. In addition, compounds that are assumed to be identical with K-252 or KT-5556 have been reported as antibacterial substances [M. Senzaki et al., J. Antibiotics, 38, 1437 (1985)]. In this publication, a compound of the above formula wherein $R_A = CO_2CH_3$ and $R_B = COCH_3$ is also disclosed. The compound assumed to be identical with K-252 and its halogen derivatives are disclosed in Japanese Published Unexamined Patent Application Nos. 120388/87 and 164626/87 and derivatives wherein R_A is modified are disclosed in Japanese Published Unexamined Patent Application No. 240689/87, all as the compounds possessing hypotensive action and diuretic action.


Furthermore, Staurosporine having the following structure and antibacterial activity is known as a compound having a structure relatively akin to that of K-252 [S. Omura et al., J. Antibiotics, 30, 275 (1977); A. Furusaki et al., J. Chem. Soc. Chem. Commun., 800 (1978); Japanese Published Unexamined Patent Application No. 185719/85].



Staurosporine

A novel active ingredient for an anti-tumor agent, etc. which has a high C-kinase inhibitory activity is always in demand.

According to the present invention, there are provided novel derivatives of K-252 represented by the formula (I):



wherein R¹ and R² are independently H or OH; X represents COOH, COOR or CH₂OH; Y represents H, R or COR; and Z represents OH, OR or SR, wherein R represents lower alkyl.

Compound (I) has C-kinase inhibitory activity and is expected to be useful as an active ingredient of anti-tumor agents etc.

The compounds represented by formula (I) are hereinafter referred to as Compound (I). Compounds represented by formulae with other numbers are referred to similarly. Compound (I) possesses an excellent C-kinase inhibitory activity and also possesses cell growth inhibitory activity.

In the definitions of formula (I), the lower alkyl includes a straight chain or branched alkyl having 1 to 4 carbon atoms, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl and t-butyl.

The compounds of the present invention can be obtained as diastereoisomers at the carbon to which the group Z is bound using, as a starting compound, K-252, etc. which are optically active. All possible stereoisomers and mixtures thereof are also included in the present invention.


Processes for producing Compound (I) are described below. However, production of Compound (I) is not deemed to be limited to these processes.

Compound (I) can be produced from K-252, etc. represented by formula (II) by various synthetic means.

In the processes shown below, in cases where the defined groups change under the conditions shown or are inadequate for the practice of the processes, the processes can be easily operated by applying thereto means conventionally used in organic synthetic chemistry, for example, protection of functional groups and removal of the protective groups [e.g., Green: Protective Groups in Organic Synthesis, John Wiley & Sons Incorporated (1981)].

Process 1: Synthesis of Compound (I-1) wherein Z is introduced into the lactam ring of Compound (III)



1-1: Compound wherein Z is OR (I-1-1)



In the formulae, R^1 , R^2 , X, Y and R have the same significances as defined above.

Compound (I-1-1) can be obtained by subjecting Compound (III) [including Compound (II)] to reaction with lead tetraacetate in acetic acid and then treating the compound with a large excess of an alcohol (IV). Lead tetraacetate is used in an amount of 1 to 1.1 equivalents based on Compound (III). The reaction is usually carried out at room temperature and completed in 7 to 10 hours.


1-2: Compound wherein Z is OH (I-1-2)



In the formulae, R^1 , R^2 , X, Y and R have the same significances as defined above.

Compound (I-1-2) can be obtained by subjecting Compound (I-1-1) obtained in Process 1 to reaction in hydrated dioxane in the presence of a suitable acid catalyst, for example, camphorsulfonic acid. The acid is used in an amount of 0.04 to 0.05 equivalent based on Compound (I-1-1). Hydrated dioxane contains 20 to 50% water. The reaction is usually carried out at 80 to 100 °C and completed in 4 to 5 hours.

1-3: Compound wherein Z is SR (I-1-3)



In the formulae, R^1 , R^2 , X, Y and R have the same significances as defined above and R^a represents H or R.



Compound (I-1-3) can be obtained by subjecting Compound (I-1-1) or (I-1-2) to reaction with a thiol (V) in an appropriate inert solvent, for example, tetrahydrofuran (THF) in the presence of a suitable acid catalyst, for example, camphorsulfonic acid. Compound (V) and the acid catalyst are used in large excess and in an amount of 0.02 to 0.05 equivalent, respectively, based on Compound (I-1-1) or (I-1-2). The reaction is usually carried out at room temperature and completed in 0.5 to one hour.

In Process 1 above, in cases where the group X or OY or the like is a functional group inadequate for the reaction, the aforesaid steps such as protection of the functional group and removal of the protective group can be suitably added (for example, see Examples 3, 8, etc.).

Compound (I-1) obtained by Process 1 can be used as the intermediates for further synthesizing novel K-252 derivatives by Processes 2, 3, etc. described below.

Process 2: Synthesis of Compound (I-2) wherein X is modified

2-1: Compound (I-2-1) wherein X is COOR



Compound (I-2-1) can be obtained by adding an alcohol (VI) and an excess amount of thionyl chloride to Compound (I-1a) [Compound (I-1) wherein X is COOH] and heating the mixture under reflux. Thionyl chloride is usually used in an amount of about one tenth (volume ratio) of the amount of Compound (VI) used also as a solvent. The reaction is carried out in the range of 60° C to the boiling point of Compound (VI) and almost completed in an hour to one day.

2-2: Compound (I-2-2) wherein X is CH₂OH





5

三

5

三




40 In the formulae, R^4 represents R; Hal represents a halogen; and R^1 , R^2 , R, X and Z have the same significances as defined above.



45 Compound (I-3-1) can be obtained by subjecting Compound (I-1b) [Compound (I-1) wherein Y is H] to reaction with a lower alkyl halide (VII) in a solvent inert to the reaction in the presence of a base. As Compound (VII), iodides and bromides which are highly reactive are preferred. The base includes sodium hydride, potassium t-butoxide, etc. Compound (VII) and the base are usually used in an equivalent amount based on Compound (I-1b). The inert solvent includes dimethylformamide (DMF), THF, etc. The reaction is usually carried out at 0° C to room temperature and completed in 20 minutes to one hour.

50 3-2: Compound (I-3-2) wherein Y is COR

55



(I-1b)



(I-3-2)

In the formulae, R^5 represents R, and R^1 , R^2 , R, X and Z have the same significances as defined above. Compound (I-3-2) can be obtained by subjecting Compound (I-1b) to reaction with an acylating agent [$(R^5\text{CO})_2\text{O}$, $R^5\text{COCl}$, or the like] in the presence of a base. The base includes pyridine, triethylamine, etc. The acylating agent is used in an amount of 1 to 2 equivalents based on Compound (I-1b). The reaction is usually carried out in pyridine as the solvent at 0 to 30°C and completed in 1 to 12 hours.

By operating the above-described Processes 1 to 3 in a suitable combination, Compound (I) having a desired functional group at a desired position can be obtained.

Compound (I) can also be obtained by applying Process 2 or 3 to the lactam (III) [including Compound (II)] and then applying Process 1.

In each of the foregoing processes, isolation and purification of the product after completion of the reaction can be carried out by methods used in conventional organic synthesis, for example, by an appropriate combination of extraction, crystallization, chromatography, etc.

Compound (I) shows a marked cell growth inhibitory activity against human uterine cervical cancer HeLa cells, human breast cancer cell MCF7, human colon adenocarcinoma cell COLO320DM, human lung differentiated squamous cell carcinoma cell PC-10, etc. and accordingly, anti-tumor compositions comprising compound (I) as an effective ingredient are provided.

When Compound (I) is used as an anti-tumor composition, each compound is dissolved in physiological saline or a solution of glucose, lactose or mannitol for injection, and usually intravenously administered as an injection in a dose of 0.01 to 20 mg/kg. Alternatively, the compound may be freeze-dried in accordance

with the Japanese Pharmacopoeia or may be prepared into injectable powder by adding sodium chloride thereto. Further, the anti-tumor composition may also contain pharmacologically acceptable well-known diluents, adjuvants and/or carriers such as salts which satisfy requirements for medical use. In cases where the compound is used as an injection, it is sometimes preferred to use auxiliary agents which enhance the solubility. Doses may be appropriately varied depending upon the age and conditions. Administration schedule can also be varied depending upon the conditions and dose. For example, the compound is administered once a day (by single administration or consecutive administration) or intermittently by one to three times a week or once every three weeks. Further, oral administration and rectal administration are also possible in the same dose and in the same manner. The compound can be administered, with appropriate adjuvants, as tablets, powders, granules, syrup, etc. for oral administration and as suppositories for rectal administration.

Representative examples of Compound (I) obtained by the processes described above are shown in Table 1 and the intermediates thereof are shown in Table 2. Examples of preparation of the Compound (I), examples of preparation of the intermediates thereof and pharmacological activities of representative Compound (I) are shown in Examples, Reference Examples and Experimental Examples, respectively.

20

25

30

35


40

45

50

55


Table 1—



30

Compound No.	Example No.	R ¹	R ²	X	Y	Z
1	1	H	H	CO ₂ CH ₃	CH ₃	OCH ₃
2	2	H	H	CO ₂ CH ₃	COCH ₃	OC ₂ H ₅
3	3	H	H	CO ₂ CH ₃	H	OC ₂ H ₅
35	4	H	H	CO ₂ CH ₃	H	SC ₂ H ₅
5	5	H	H	CO ₂ CH ₃	H	OH
6	6	H	H	CH ₂ OH	H	OH
40	7	H	H	CH ₂ OH	H	SC ₂ H ₅
8	8	OH	H	CO ₂ CH ₃	H	OH

Table 2 Intermediates



Reference						
Compound	Example	R ¹	R ²	R ⁶	X _A	Y _A
No.	No.					
a	1	H	H	H	CO ₂ CH ₃	OCH ₃
b		H	H	H	CO ₂ CH ₃	OCOCH ₃
c	2	H	H	COCH ₃	CO ₂ CH ₃	OCOCH ₃
d	3	COCH ₃	H	COCH ₃	CO ₂ CH ₃	OCOCH ₃
e	4	OCOCH ₃	H	COCH ₃	CO ₂ CH ₃	OCOCH ₃
f	5	OH	H	H	CO ₂ CH ₃	OH
g	6	OCOCH ₃	H	H	CO ₂ CH ₃	OCOCH ₃

Example 1

Compound a (481 mg, 1 mmol) obtained in Reference Example 1 was dissolved in 50 ml of acetic acid and 488 mg (1.1 mmol) of lead tetraacetate was added to the solution, followed by stirring under shading at room temperature for 8 hours. After the solvent was distilled off under reduced pressure, 50 ml of THF was added to the residue. The mixture was washed successively with saturated sodium bicarbonate aqueous solution and saturated sodium chloride aqueous solution and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and the residue was purified by silica gel column chromatography (1% methanol/chloroform) to give 203 mg (40%) of Compound 1.

NMR (CDCl₃) δ: 2.08-2.44 (m, 1H), 2.20 and 2.22 (s, 3H), 3.14 and 3.18 (s, 3H), 3.42 (m, 1H), 4.04 (s, 3H), 6.36 (m, 1H), 6.64 and 6.66 (s, 1H), 7.02 (dd, 1H, J = 5, 7Hz), 7.36-7.64 (m, 5H), 7.92 (m, 1H), 8.46 (m, 1H), 9.33 (d, 1H, J = 8Hz)

MS (m/z): 512 (M + 1)⁺

Example 2

Compound b (see Table 2) [J. Antibiotics, **38**, 1437 (1985)] (253 mg, 0.5 mmol) was oxidized in a similar manner as in Example 1 and subjected to silica gel column chromatography with 0.5% ethanol:chloroform as the solvent to give 191 mg (73%) of Compound 2.

NMR (CDCl₃) δ: 1.00-1.28 (m, 3H), 1.68 and 1.70 (s, 3H), 2.00-2.40 (m, 1H), 2.19 and 2.21 (s, 3H), 3.36-4.04 (m, 3H), 3.92 (s, 3H), 6.49 and 6.53 (s, 1H), 7.16-7.72 (m, 4H), 7.99 (d, 2H, J = 8Hz), 8.34 (d, 1H, J = 8Hz), 9.16 (d, 1H, J = 8Hz)

MS (m/z): 554 (M + 1)⁺

Example 3

Compound 2 (1.01 g, 1.87 mmol) obtained in Example 2 was dissolved in 50 ml of dichloromethane and 1.81 ml of 28% sodium methylate was added to the solution under ice cooling. The mixture was stirred at the same temperature for 0.5 hour. To the reaction solution was added 10 ml of saturated sodium chloride aqueous solution. After the dichloromethane layer was separated, the aqueous layer was extracted with THF and the extract was combined with the dichloromethane layer. The mixture was dried over anhydrous magnesium sulfate, and the solvent was distilled off under reduced pressure. The residue was purified by silica gel column chromatography (50% acetone:ethanol) to give 900 mg (97%) of Compound 3.

NMR (DMSO-d₆) δ: 1.16 (br, t, 3H), 1.94-2.24 (m, 1H), 2.15 (s, 3H), 3.00-4.00 (m, 3H), 3.92 (s, 3H), 6.50 (s, 1H), 7.14 (m, 1H), 7.24-8.40 (m, 7H), 9.04 (br.s, 1H), 9.13 (d, 1H, J = 7Hz)

MS (m/z): 512 (M + 1)⁺

Example 4

Compound 3 (250 mg, 0.5 mmol) obtained in Example 3 was dissolved in 10 ml of THF, and 0.74 ml of ethyl mercaptan and 10 mg of camphorsulfonic acid were added to the solution. The mixture was stirred at room temperature overnight. The solvent was distilled off under reduced pressure and the residue was purified by silica gel column chromatography (1% methanol:chloroform) to give 156 mg (59%) of Compound 4.

NMR (DMSO-d₆) δ: 1.14 and 1.16 (s, 3H), 1.90-2.88 (m, 3H), 2.13 and 2.16 (s, 3H), 3.00-3.56 (m, 1H), 3.92 (s, 3H), 6.32 (s, 0.55H), 6.45 (s, 0.45H), 6.55 and 6.57 (s, 1H), 7.00-8.00 (m, 7H), 8.32-8.56 (m, 1H), 9.12-9.26 (m, 2H)

MS (m/z): 528 (M + 1)⁺

Example 5

Compound 3 (497 mg, 1 mmol) obtained in Example 3 was dissolved in 10 ml of dioxane and 4 ml of water, and 10 mg of camphorsulfonic acid was added to the solution. The mixture was heated under reflux for 4 hours. To the reaction solution was added 20 ml of THF and the mixture was washed successively with saturated sodium bicarbonate aqueous solution and saturated sodium chloride aqueous solution and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and the residue was purified by silica gel column chromatography (20% acetone:toluene) to give 292 mg (60%) of Compound 5.

NMR (DMSO-d₆) δ: 1.88-2.20 (m, 1H), 2.12 (s, 3H), 3.24-3.60 (m, 1H), 3.90 (s, 3H), 6.31 and 6.38 (s, 1H), 6.24 (br.s, 2H), 7.00-7.60 (m, 5H), 7.80-8.00 (m, 2H), 8.43 (m, 1H), 8.80 (s, 1H), 9.12(d, 1H, J = 8Hz)

MS (m/z): 484 (M + 1)⁺

Example 6

Compound 5 (67 mg, 0.14 mmol) obtained in Example 5 was dissolved in 2 ml of THF and 0.2 ml of

water, and 16 mg (0.42 mmol) of sodium borohydride was added to the solution under ice cooling. The mixture was stirred at the same temperature for 2 hours. The reaction solution was washed with saturated sodium chloride aqueous solution and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and the residue was triturated with THF-ether to give 53 mg (83%) of powdery Compound 6.

NMR (DMSO- d_6) δ : 1.96-2.28 (m, 1H), 2.14 (s, 3H), 3.00-4.00 (m, 3H), 5.08 (m, 1H), 5.32-5.48 (m, 1H), 6.44 (m, 2H), 6.80-8.50 (m, 8H), 8.75 (s, 1H), 9.12 (d, 1H, $J=8\text{Hz}$)
MS (m/z): 456 (M+1)

Example 7

Compound 4 (109 mg, 0.21 mmol) obtained in Example 4 was reduced in a similar manner as in Example 6 to give 72 mg (69%) of Compound 7.

NMR (DMSO- d_6) δ : 1.00-1.28 (m, 3H), 1.92-2.40 (m, 1H), 2.12 and 2.16 (s, 3H), 3.00-3.40 (m, 1H), 3.80 (m, 2H), 5.08 (m, 1H), 5.36 and 5.52 (s, 1H), 6.51 and 6.53 (s, 1H), 6.96 (m, 1H), 7.12-8.52 (m, 7H), 9.14 (br. s, 1H), 9.16 (d, 1H, $J=8\text{Hz}$)
MS (m/z): 500 (M+1)

Example 8

Compound g (227 mg, 0.41 mmol) obtained in Reference Example 6 was oxidized in a similar manner as in Example 1 to obtain Compound (I: $R^1 = \text{OCOCH}_3$, $R^2 = \text{H}$, $X = \text{CO}_2\text{CH}_3$, $Y = \text{COCH}_3$, $Z = \text{OCH}_3$). The obtained compound was treated in a similar manner as in Example 5 to give Compound (I: $R^1 = \text{OCOCH}_3$, $R^2 = \text{H}$, $X = \text{CO}_2\text{CH}_3$, $Y = \text{COCH}_3$, $Z = \text{OH}$). Without purifying this compound, the protective groups were removed in a similar manner as in Example 3 to give 25 mg (12.6%) of Compound 8.

NMR (CDCl₃-DMSO- d_6) δ : 2.00-2.36 (m, 1H), 2.16 and 2.19 (s, 3H), 3.08-3.48 (m, 1H), 3.99 (s, 3H), 6.20-6.60 (m, 3H), 6.84-8.04 (m, 5H), 8.36-8.76 (m, 3H), 8.89 (s, 1H)
MS (m/z): 500 (M+1)

Reference Example 1

A solution of 184 mg (0.4 mmol) of K-252 in 2 ml of DMF was ice cooled and 19.2 mg (0.4 mmol) of 50% oily sodium hydride was added to the solution. After 20 minutes, 25 μl (0.4 mmol) of methyl iodide was added to the mixture, followed by stirring for one hour. To the reaction mixture was added 20 ml of chloroform, and the resulting solution was washed with water and dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography (chloroform) to give 65 mg (34%) of Compound a as pale yellow powder.

Melting point: 250 - 252 °C (recrystallized from chloroform-methanol)

NMR (CDCl₃) δ : 9.42 (d, 1H, $J=8\text{Hz}$), 8.1-7.85 (m, 2H), 7.7-7.2 (m, 5H), 7.03 (dd, 1H, $J=5, 7\text{Hz}$), 5.08 (s, 2H), 4.05 (s, 3H), 3.37 (dd, 1H, $J=7, 14\text{Hz}$), 3.13 (s, 3H), 2.21 (s, 3H), ca. 2.20 (dd, 1H)
MS (m/z): 481 (M)

Reference Example 2

K-252 (2 g, 4.2 mmol) was dissolved in 10 ml of THF, and 4 ml of acetic anhydride and 2.6 g of dimethylaminopyridine were added to the solution. After being stirred at room temperature overnight, the reaction solution was washed successively with 2% hydrochloric acid aqueous solution and saturated sodium chloride aqueous solution and then dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure and the residue was purified by silica gel column chromatography (chloroform) to give 2.12 g (94%) of Compound c and pale yellow powder.

NMR (CDCl₃) δ : 1.76 (s, 3H), 2.03 (dd, 1H, $J=5, 14\text{Hz}$), 2.16 (s, 3H), 2.56 (s, 3H), 3.86 (dd, 1H, $J=7, 14\text{Hz}$), 3.98 (s, 3H), 5.07 (s, 2H), 6.93 (dd, 1H, $J=5, 7\text{Hz}$), 7.14-7.66 (m, 5H), 7.80-8.00 (m, 2H), 9.02 (d, 1H, $J=8\text{Hz}$)

Reference Example 3

Compound c (110 mg, 0.2 mmol) obtained in Reference Example 2 was dissolved in 10 ml of dichloromethane, and 133 mg (1 mmol) of aluminum chloride and 0.015 ml (0.2 mmol) of acetyl chloride were added to the solution under ice cooling. The mixture was stirred at the same temperature for 2 hours. To the mixture was added 10 ml of water, and the organic layer was separated. The organic layer was then washed with saturated sodium chloride aqueous solution and dried over anhydrous magnesium sulfate. The residue was purified by silica gel column chromatography (chloroform) and recrystallized from chloroform-methanol to give 60 mg (50.8%) of Compound d as colorless prisms having a melting point higher than 300 °C.

NMR (CDCl₃) δ: 1.76 (s, 3H), 1.09 (dd, 1H, J=5, 14Hz), 2.28 (s, 3H), 2.52 (s, 3H), 2.69 (s, 3H), 3.93 (dd, 1H, J=7, 14Hz), 4.01 (s, 3H), 5.20 (s, 3H), 6.89 (dd, 1H, J=5, 7Hz), 7.28-7.72 (m, 3H), 7.88-8.24 (m, 3H), 9.68 (s, 1H)

MS (m/z): 594 (M+1)⁺

Reference Example 4

Compound d (20 mg, 0.033 mmol) obtained in Reference Example 3 was dissolved in 1 ml of chloroform, and 25 mg (0.15 mmol) of m-chloroperbenzoic acid was added to the solution twice at an interval of one hour, followed by heating under reflux for 3 hours. After washing with saturated sodium bicarbonate aqueous solution and water, the mixture was dried over anhydrous magnesium sulfate. The solvent was distilled off under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform) and recrystallized from chloroform-ether to give 10 mg (48.0%) of Compound e as brown powder having a melting point higher than 300 °C.

NMR (CDCl₃) δ: 1.79 (s, 3H), 2.09 (dd, 1H, J=5, 14Hz), 2.26 (s, 3H), 2.40 (s, 3H), 2.70 (s, 3H), 3.94 (dd, 1H, J=7, 14Hz), 4.00 (s, 3H), 5.34 (s, 2H), 6.98 (dd, 1H, J=5, 7Hz), 7.20-7.70 (m, 3H), 7.92-8.20 (m, 3H), 8.90 (d, 1H, J=2Hz)

MS (m/z): 610 (M+1)⁺

Reference Example 5

Compound f (0.3 g, 38.8%) was obtained from 1.0 g (1.6 mmol) of Compound e obtained in Reference Example 4 in a similar manner as in Example 3 as reddish brown prisms having a melting point higher than 300 °C (recrystallized from chloroform).

NMR (DMSO-d₆) δ: 1.97 (dd, 1H, J=5, 14Hz), 2.12 (s, 3H), 3.35 (dd, 1H, J=7, 14Hz), 3.92 (s, 3H), 5.01 (s, 2H), 6.32 (s, 1H), 6.88-7.16 (m, 2H), 7.28-7.64 (m, 2H), 7.72 (d, 1H, J=8Hz), 7.80-8.20 (m, 2H), 8.60 (s, 1H), 8.71 (d, 1H, J=2Hz), 9.10 (s, 1H)

MS (m/z): 481 (M+1)⁺

Reference Example 6

Compound f (241 mg, 0.5 mmol) obtained in Reference Example 5 was dissolved in 5 ml of pyridine and 1 ml of acetic anhydride was added to the solution, followed by stirring at room temperature for 6 days. The solvent was distilled off under reduced pressure and the residue was purified by silica gel column chromatography (1% methanol/chloroform) to give 247 mg (87.3%) of Compound g.

NMR (DMSO-d₆) δ: 1.69 (s, 3H), 2.04-2.40 (m, 1H), 2.23 (s, 3H), 2.36 (s, 3H), 3.88 (dd, 1H, J=7, 14Hz), 3.94 (s, 3H), 5.03 (s, 2H), 7.20-8.20 (m, 6H), 8.67 (s, 1H), 8.88 (d, 1H, J=2Hz)

MS (m/z): 568 (M+1)⁺

Experimental Example

Compound (I) obtained by the present invention was examined for C-kinase inhibitory activity and cell growth inhibitory activity by the following methods. The results are shown in Table 3.

C-Kinase inhibitory activity test:

C-Kinase inhibitory activity of representative Compounds (I) was measured in accordance with the method of Y. Nishizuka, et al. [J. Biol. Chem., 257, 13341 (1982)]. The test was carried out on test compounds at varied concentrations, and the concentration at which the enzyme activity was inhibited 50% (IC₅₀) was determined.

Cell growth inhibition tests:

10

(1) MCF7 cell growth inhibition test:

MCF7 cells (4.5×10^4 cells/ml) prepared in RPMI 1640 medium containing 10% fetal calf serum, 10 $\mu\text{g/ml}$ insulin and 10^{-8} M estradiol are put into wells of a 96-well microtiter plate in the amount of 0.1 ml per each well. After incubation at 37 °C overnight in CO₂-incubator, 0.05 ml of a test sample appropriately diluted with the culture medium is added to each well. The cells are further cultured in CO₂-incubator, and then the culture supernatant is removed and the wells are washed once with PBS(-). Thereafter, 0.1 ml of fresh medium is added to each well, followed by culturing at 37 °C for 72 hours in CO₂-incubator. After the culture supernatant is removed, 0.1 ml of the culture medium containing 0.02% Neutral Red is added to each well, followed by culturing at 37 °C for one hour in CO₂-incubator, whereby the cells are stained. Then, the culture supernatant is removed and the cells are washed once with physiological saline. The pigment is extracted with 0.001 N hydrochloric acid/30% ethanol and absorption is measured at 550 nm with a microplate reader. By comparing the absorption of intact cells with those of the cells treated with a test compound at known concentrations, the concentration of the test compound at which growth of the cells is inhibited 50% is calculated as IC₅₀.

30

(2) HaLaS₃ cell growth inhibition test:

HeLaS₃ cells (3×10^4 cells/ml) prepared in MEM medium containing 10% fetal calf serum and 2 mM glutamine are put into wells of a 96-well microtiter plate in the amount of 0.1 ml per each well. Thereafter, the test is carried out in the same manner as in (1).

35

(3) COLO320DM cell growth inhibition test:

COLO320DM cells (10^5 cells/ml) prepared in RPMI 1640 medium containing 10% fetal calf serum, 100 U/ml penicillin and 100 $\mu\text{g/ml}$ streptomycin are put into wells of a 96-well microtiter plate in the amount of 0.1 ml per each well. Thereafter, the test is carried out in the same manner as in (1) except that the cells are counted with a microcell counter. By comparing the number of intact cells with those of the cells treated with a test compound at known concentrations, the concentration of the test compound at which growth of the cells is inhibited 50% is calculated as IC₅₀.

45

Table 3


C-Kinase Inhibitory Activity and Cell Growth Inhibitory Activity of Synthesized Compounds				
Compound No.	C-Kinase	IC ₅₀ ($\mu\text{g/ml}$) HeLaS ₃	MCF7	COLO320DM
5	1.2	1.53	0.80	2.55
7	0.18	1.43	5.08	1.00
K-252 (reference compound)	0.016	0.2	0.51	0.27

55

Also included within the scope of the invention are pharmaceutically acceptable salts of the K-252 derivatives described, and pharmaceutical compositions containing them.

Claims

1. K-252 derivatives of the formula:



25 in any and all stereoisomeric forms, wherein R^1 and R^2 are independently H or OH; X represents COOH, COOR, or CH_2OH ; Y represents H, R or COR; and Z represents OH, OR or SR, wherein R represents lower alkyl.

2. Compounds of the formula defined claim 1, wherein the definitions of X, Y and Z, R is a straight chain or branched alkyl group having 1 to 4 carbon atoms.

30 3. The compound according to claim 1, in any and all stereoisomeric forms, wherein R^1 and R^2 are H, X is $COOCH_3$, Y is CH_3 and Z is OCH_3 .

4. The compound according to claim 1, in any and all stereoisomeric forms, wherein R^1 and R^2 are H, X is $COOCH_3$, Y is $COCH_3$ and Z is OC_2H_5 .

35 5. The compound according to claim 1, in any and all stereoisomeric forms, wherein R^1 and R^2 are H, X is $COOCH_3$, Y is H and Z is OC_2H_5 .

6. The compound according to claim 1, in any and all stereoisomeric forms, wherein R^1 and R^2 are H, X is $COOCH_3$, Y is H and Z is SC_2H_5 .

7. The compound according to claim 1, in any and all stereoisomeric forms, wherein R^1 and R^2 are H, X is $COOCH_3$, Y is H and Z is OH.

40 8. The compound according to claim 1, in any and all stereoisomeric forms, wherein R^1 and R^2 are H, X is CH_2OH , Y is H and Z is OH.

9. The compound according to claim 1, in any and all stereoisomeric forms, wherein R^1 and R^2 are H, X is CH_2OH , Y is H and Z is SC_2H_5 .

45 10. The compound according to claim 1, in any and all stereoisomeric forms, wherein R^1 is OH, R^2 is H, X is $COOCH_3$, Y is H and Z is OH.

11. Pharmaceutically acceptable salts of the K-252 derivatives claimed in claim 1 or 2.

12. A pharmaceutical composition comprising a K-252 derivative of the formula defined in claim 1 or 2, or a pharmaceutically acceptable salt thereof, in admixture with a pharmaceutically acceptable carrier or diluent.

50 13. A composition according to claim 12, wherein the K-252 derivative is a compound as claimed in any one of claims 3 to 10.

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets

(11) Publication number:

0 323 171
A3

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 88312251.7

(51) Int. Cl.⁵: C07H 19/23, A61K 31/70

(22) Date of filing: 22.12.88

(30) Priority: 24.12.87 JP 327857/87

(43) Date of publication of application:
05.07.89 Bulletin 89/27(84) Designated Contracting States:
DE FR GB(88) Date of deferred publication of the search report:
22.08.90 Bulletin 90/34(71) Applicant: KYOWA HAKKO KOGYO CO., LTD.
6-1, Ohte-Machi Itchome
Chiyoda-ku Tokyo(JP)(72) Inventor: Murakata, Chikara c/o Patent
Department
Kyowa Hakko Kogyo Co. Ltd. 6-1 Ohtemachi
Itchome
Chiyoda-ku Tokyo(JP)
Inventor: Sato, Akira c/o Patent Department
Kyowa Hakko Kogyo Co. Ltd. 6-1 Ohtemachi
Itchome
Chiyoda-ku Tokyo(JP)

Inventor: Kasai, Masaji c/o Patent Department
Kyowa Hakko Kogyo Co. Ltd. 6-1 Ohtemachi
Itchome

Chiyoda-ku Tokyo(JP)

Inventor: Kobayashi, Eiji c/o Patent
Department

Kyowa Hakko Kogyo Co. Ltd. 6-1 Ohtemachi
Itchome

Chiyoda-ku Tokyo(JP)

Inventor: Morimoto, Makoto c/o Patent
Department

Kyowa Hakko Kogyo Co. Ltd. 6-1 Ohtemachi
Itchome

Chiyoda-ku Tokyo(JP)

Inventor: Akinaga, Shiro c/o Patent
Department

Kyowa Hakko Kogyo Co. Ltd. 6-1 Ohtemachi
Itchome


Chiyoda-ku Tokyo(JP)

(74) Representative: Lambert, Hugh Richmond et
al
D. YOUNG & CO. 10 Staple Inn
London, WC1V 7RD(GB)

(54) Novel K-252 derivatives having anti-tumor activity and pharmaceutical compositions containing them.

(57) Pharmaceutically active derivatives of K-252 are disclosed, i.e. compounds of the formula:

EP 0 323 171 A3



wherein R^1 and R^2 are independently H or OH; X represents COOH, COOR, or CH_2OH ; Y represents H, R or COR; and Z represents OH, OR or SR, wherein R represents lower alkyl. Such compounds have C-kinase inhibitory activity and are expected to be useful as an active ingredient of anti-tumor pharmaceutical preparations, etc.



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
Y	EP-A-0 238 011 (KYOWA HAKKO KOGYO CO. LTD) * Page 3; page 12, claims 1-5 * ---	1,11-13	C 07 H 19/23 A 61 K 31/70
Y,D	CHEMICAL ABSTRACTS, vol. 107, no. 21, 23rd November 1987, page 725, abstract no. 197943s, Columbus, Ohio, US; & JP-A-62 120 388 (MEIJI SEIKA KAISHA, LTD) 01-06-1987 * Abstract * ---	1,11-13	
X,P	CHEMICAL ABSTRACTS, vol. 111, no. 21, 20th November 1989, page 743, abstract no. 194456g, Columbus, Ohio, US; & JP-A-63 295 589 (KYOWA HAKKO KOGYO CO., LTD) 01-12-1988 * Abstract * ---	1,2,11-13	
A,D	JOURNAL OF ANTIBIOTICS, vol. 38, no. 10, October 1985, pages 1437-1439; M. SEZAKI et al.: "A new antibiotic SF-2370 produced by actinomadura" * Page 1438, column 1, structures 1-4; page 1437, column 1, lines 1-10 * ---	1	TECHNICAL FIELDS SEARCHED (Int. Cl.4) C 07 H 19/00 A 61 K 31/00
A,D	CHEMICAL ABSTRACTS, vol. 108, no. 25, 20th June 1988, page 551, abstract no. 221497t, Columbus, Ohio, US; & JP-A-62 240 689 (MEIJI SEIKA KAISHA, LTD) 21-10-1987 * Abstract * --- -/-	1	
The present search report has been drawn up for all claims			
Place of search THE HAGUE		Date of completion of the search 25-05-1990	Examiner SCOTT J.R.M.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document			



DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl. 4)
A,D	CHEMICAL ABSTRACTS, vol. 104, "no. 3, 20th January 1986, page 404, abstract no. 18649u, Columbus, Ohio, US; & JP-A-60 185 719 (AJINOMOTO CO., INC.) 21-09-1985 * Abstract * ---	1	
A	EP-A-0 269 025 (BRISTOL MYERS CO.) * Abstract; page 2; page 5, formula IV; claims 1-15 * ---	1	
A,D	JOURNAL OF THE CHEMICAL SOCIETY, CHEMICAL COMMUNICATIONS, no. 18, 20th September 1978, pages 800-801; A. FURUSAKI et al.: "X-ray crystal structure of staurosporine: A new alkaloid from a Streptomyces strain" * The whole document * -----	1	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int. Cl.4)
Place of search THE HAGUE		Date of completion of the search 25-05-1990	Examiner SCOTT J.R.M.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document			